BRHELOVÁ, Eliška, Radka OPATŘILOVÁ, Peter SCHEER, Jana HLOŽKOVÁ, Sandra THALEROVÁ, Ahmet Davut AKSU and Robert MIKULÍK. FASTER THROMBOLYSIS IN VIVO. In 51st Conference Synthesis and Analysis of Drugs, Bratislava, September 7 & 8, 2023. 2023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name FASTER THROMBOLYSIS IN VIVO
Authors BRHELOVÁ, Eliška (203 Czech Republic, belonging to the institution), Radka OPATŘILOVÁ (203 Czech Republic, belonging to the institution), Peter SCHEER (203 Czech Republic, belonging to the institution), Jana HLOŽKOVÁ (203 Czech Republic, belonging to the institution), Sandra THALEROVÁ (203 Czech Republic), Ahmet Davut AKSU (792 Turkey, belonging to the institution) and Robert MIKULÍK (203 Czech Republic).
Edition 51st Conference Synthesis and Analysis of Drugs, Bratislava, September 7 & 8, 2023, 2023.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Slovakia
Confidentiality degree is not subject to a state or trade secret
WWW Odborný program konference - sborník abstrakt
RIV identification code RIV/00216224:14160/23:00134678
Organization unit Faculty of Pharmacy
Keywords (in Czech) tromboembolie; skiaskopie; ischemická cévní mozková příhoda; altepláza
Keywords in English thromboembolism; micro-fluoroscopy; ischemic stroke; limb ischemia; alteplase
Tags rivok, ÚChL, ÚFTo
Changed by Changed by: Mgr. Daniela Černá, učo 489184. Changed: 29/2/2024 09:04.
Abstract
This innovative experimental work focuses on the development of targeted thrombolytics combinations for the diagnosis and therapy of cerebral infarction, their preparation and testing in a rat animal model. The effect of the addition of plasminogen to the standard recombinant alteplase in the treatment of cerebral infarction was tested. A rat model of systemic embolism was used for this purpose. The design of the model is set to simulate as much as possible the course of thrombolysis in the human organism and the implementation of preclinical research into clinical practice is realistic.
Links
NU21-08-00510, research and development projectName: Biokompatibilní nanočástice jako cílené systémy pro dodávání léčiv a teranostik pro léčbu cévní mozkové příhody
Investor: Ministry of Health of the CR
NU23-08-00499, research and development projectName: Zlepšení účinnosti a bezpečnosti rekanalizace mozkového infarktu pomocí duální trombolytické terapie
Investor: Ministry of Health of the CR, Subprogram 1 - standard
PrintDisplayed: 31/5/2024 18:31